Clinical trial · Interventional
Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
Early Assessment of Anti-Angiogenic Treatment Efficacy in Advanced Renal Cancer by Using Contrast-Enhanced Sonography
NCT01105364CI-TRIAL-00011696unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or bevacizumab, and allow doctors to plan better treatment. PURPOSE: This clinical trial is studying ultrasonography in assessing antiangiogenic treatment in patients with advanced kidney cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| antiangiogenesis therapy | Drug | — | UNRESOLVED |
| computed tomography | Procedure | — | UNRESOLVED |
| imaging biomarker analysis | Other | — | UNRESOLVED |
| magnetic resonance imaging | Procedure | — | UNRESOLVED |
| pharmacological study | Other | — | UNRESOLVED |
| stabilized sulphur hexafluoride microbubble-based contrast agent | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (8)
- measure
- Lesion size (main diameter)
- measure
- Arrival time within lesion
- measure
- Time-to-peak
- measure
- β parameter from enhancement curve
- measure
- Density of microvessels at peak enhancement
- measure
- Enhancement ratio between the lesion and the surrounding parenchyma at peak value
- measure
- Determination of necrotic and viable volume
- measure
- Tumoral response determined by RECIST criteria
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of advanced renal cancer * Planning to receive antiangiogenic treatment * Detection of a target hepatic metastasis that is visible, located, and sized with conventional sonography and CT scan and/or MRI PATIENT CHARACTERISTICS: * No active cardiac disease * No severe arterial hypertension PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.